5.4. biopsy indication. 5.4.1. risk assessment mri biopsy elevated risk significant pca established based one primary diagnostic tools applied, psa level, dre, primary imaging. classic diagnostic algorithm indication biopsy generally solely based psa-threshold abnormal dre, different two- three-tier sequential / conditional pathways available indicate prostate biopsy, imaging and/or biomarkers. combined and/or sequenced two multiple-tier conditional diagnostic pathways (e.g. psa -> mri, psa -> risk calculator, psa -> risk calculator -> mri, etc). age, co-morbidity, life expectancy, therapeutic consequences also considered discussed beforehand . chosen diagnostic algorithm may elected based availability, expertise, resources. different approaches impact cancer detection rates, number (un)necessary biopsies, number patient visits, option targeted biopsies. elected strategy may also decided based prevalence disease men entering pathway (e.g. screening versus clinical symptoms). different sequences combinations tools, lead different rates biopsy indications, detection rates insignificant pca, significant pca, also burden costs diagnostic algorithm . 5.4.1.1. risk calculators assessing risk cspca different steps diagnostic process, available parameters may combined risk calculators optimise risk-assessment cspca. validation adaption target population important issues use. risk calculators, combining clinical data (age, dre findings, psa level, prostate volume, etc.) may useful helping determine (on individual basis) potential risk cancer may be, thereby improving balance cancer detection rates number biopsies . several tools developed cohort studies available including (among others) calculator derived erspc cohort (http://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators) updated incorporating 2014 isup pathology gleason grading cribriform growth , one derived prostate cancer prevention trial (pcpt) cohort (pcptrc 2.0 https://riskcalc.org/pcptrc/). however, calculators limited dependency disease prevalence. calculators show miscalibration tested populations different prevalence training population model. recalibrations taking account local prevalence possible, approach difficult routine local prevalence difficult estimate may change time. 5.4.1.2. using risk-stratification avoid magnetic resonance imaging scans biopsy procedures retrospective analysis including 200 men prospective database patients underwent mri combined systematic targeted biopsy showed upfront use rotterdam prostate cancer risk calculator would avoided mri biopsy 73 men (37%). 73 men, ten isup grade group 1 cancer 4 isup grade group ≥ 2 cancer . prospective multi-centre study evaluated several diagnostic pathways 545 biopsy-naive men underwent mri systematic targeted biopsy. using phi threshold > 30 perform mri biopsy would avoided mri biopsy 25% men cost missing 8% isup grade group ≥ 2 cancers . another prospective multi-centre trial including 532 men (with without history prostate biopsy) showed using threshold ≥ 10% stockholm3 test perform mri biopsy would avoided mri biopsy 38% men cost missing 8% isup grade group ≥ 2 cancers . finally, risk calculator developed 1,486 men underwent mri biopsy externally validated cohort 946 men two institutions; using risk threshold provided 95% sensitivity development cohort could avoided 22% mri scans validation cohort missing 5% cspca . 5.4.2. mri based indication biopsy 5.4.2.1. mri triage test biopsy (‘mri pathway’) owing high sensitivity, mri showed excellent npv ruling presence cspca subsequent biopsy , also four years follow-up . diagnostic yield number biopsy procedures potentially avoided ‘mr pathway’ (in patients positive mri undergo biopsy) depends likert/pi-rads threshold used define positive mri. pooled studies biopsy-naive patients patients prior negative biopsies, likert/pi-rads threshold ≥ 3 would avoided 30% (95% ci: 23–38) biopsy procedures missing 11% (95% ci: 6–18) detected isup grade group ≥ 2 cancers (relative percentage) . increasing threshold ≥ 4 would avoided 59% (95% ci: 43–78) biopsy procedures missing 28% (95% ci: 14–48) detected isup grade group ≥ 2 cancers . note, percentages negative mri (likert/pi-rads score ≤ 2) may show substantial variability among series. precision, mri-first 4m trials 21.1%, 28.9% 49%, related isup grade group ≥ 2 cancer prevalence 27.7% (23.7–32.6), 37.5% (31.4–43.8), 30% (nd) respectively . mr proper trial, prospective, multi-centre, non-randomised opportunistic early detection setting (psa > 3 ng/ml), comparable rates isup grade group ≥ 2 cancer detection (24% vs. 25%) obtained mri pathway strategy indicating systematic biopsy based risk calculator. however, mri pathway avoided biopsy men compared diagnostic pathway using risk calculator (559/1015, 55% vs. 403/950, 42%; difference -13%, 95% 27 ci: -17% -8.3%; p < 0.01); also detected less isup grade group 1 cancers (84/1015, 8.3% vs. 121/950, 13%; difference 4.5%, 95% ci: 1.8–7.2%; p < 0.01) . 5.4.2.2. combining mri psa density prostate-specific antigen density (psa-d) may help refine risk cspca patients undergoing mri psa-d pi-rads score significant independent predictors cspca biopsy . combinations psa-d mri explored , showing guidance biopsy-decisions whilst safely avoiding redundant biopsy testing detection insignificant pca. meta-analysis eight studies, pooled mri npv isup grade group ≥ 2 cancer 84% (95% ci: 81–87) whole cohort, 83% (95% ci: 80–84) biopsy-naive men 88% (95% ci: 85–91) men prior negative biopsies. subgroup patients psa-d < 0.15 ng/ml/cc, npv increased respectively 90% (95% ci: 87–93), 89% (95% ci: 83–93) 94% (95% ci: 91–97) . contrast, risk isup grade group ≥ 2 cancer high 27–40% patients negative mri psa-d > 0.15–0.20 ng/ml/cc [189,288,292-294]. based meta-analysis > 3,000 biopsy-naive men, risk-adapted data table cspca developed, linking pi-rads score (1-2, 3, 4-5) psa-d categories (< 0.10, 0.10–0.15, 0.15–0.20 > 0.20 ng/ml) (table 5.4) . risk-adapted matrix table may guide decision perform biopsy. multi-centre retrospective cohort 1476 men pirads 3 lesions prevalence 18.5% isup grade group ≥ 2 cancer, age, prior negative biopsy psa-d significant independent predictors presence isup grade group ≥ 2 cancer subsequent systematic targeted biopsy. applying psa-d cut-off 0.15 ng/ml/cc, 817 biopsy procedures (58.4%) would avoided cost missing isup grade group ≥ 2 cancer 91 men (6.5%); isup grade group 1 cancer would detected 115 men (8.2%) . two studies provided follow-up data patients pi-rads scores 1-3 psa-d <0.15 ng/ml/cc biopsy omitted. cumulative incidence isup grade group ≥ 2 cancer detection 1.3% two years 3.2% 36 months . table 5.4: risk data table clinically significant prostate cancer, related pi-rads score psa-d categories biopsy-naive men, clinically suspected significant disease * risk data table 1detection clinically significant prostate cancer (isup grade 2 higher)psa-density risk groupspi-rads risk categoriesprevalence isup > 2 pcalow< 0.10intermediate-low0.10–015intermediate-high0.15–0.20high> 0.2031%(678/2199)28%(612/2199)16%(360/2199)25%(553/2199)compiled totals cspca riskpi-rads 1–26%(48/839)3%(11/411)7%(17/256)8%(8/104)18%(12/68)pi-rads 316%(41/254)4%(3/74)13%(11/88)29%(12/41)29%(15/51)pi-rads 4–562%(687/1106)31%(59/189)54%(144/286)69%(148/215)77%(336/434)all pi-rads35%(776/2199)11%(73/674)28%(172/612)47%(168/360)66%(363/553)↓risk-adapted matrix table biopsy decision managementpi-rads 1–2no biopsyno biopsyno biopsyconsider biopsypi-rads 3no biopsyconsider biopsyhighly consider biopsyperform biopsypi-rads 4–5perform biopsyperform biopsyperform biopsyperform biopsy risk data table 2very low0–5% cspca (below population risk) #low5–10% cspca (acceptable risk) ##intermediate-low10–20% cspcaintermediate-high20–30% cspcahigh30–40% cspcavery high> 40% cspca # thompson im et al. n engl j med. 2004 may 27;350(22):2239-46. prevalence prostate cancer among men prostate-specific antigen level < = 4.0 ng/ml. . table adapted from: schoots, ig padhani ar. bju int 2021 127(2):175. risk-adapted biopsy decision based prostate magnetic resonance imaging prostate-specific antigen density enhanced biopsy avoidance first prostate cancer diagnostic evaluation, permission wiley. 5.4.2.3. risk calculators incorporating mri finding several groups developed comprehensive risk calculators combine mri findings simple clinical data tool predict subsequent biopsy results . calculators underwent external validation good results terms discrimination clinical utility tended outperform risk calculators incorporating mri findings [299-302]. however, use hindered miscalibration due prevalence dependency (see section 5.4.1.1). 5.4.2.4. mri screening protocols inclusion mri may improve diagnostic algorithm screening psa, reduces number men undergo biopsies detecting high-grade less low-grade pca . stockholm-3 (sthlm3) screening trial randomised men psa > 3 ng/ml standard biopsies (10–12 cores) mri standard plus targeted biopsies presence suspicious mri. percentage men underwent prostate biopsies standard group double mri group. non-inferiority trial, intention-to-treat (itt) analysis found 18% 21% isup grade group ≥2 cancer 12% 4% isup grade group 1 cancer standard mri group, respectively . göteborg-2 screening trial, 37,887 men 50 60 years age invited undergo regular psa screening . participants psa level 3 ng/ml randomly allocated mri combined systematic- targeted biopsy (reference group) mri targeted biopsy case pi-rads ≥ 3 lesions (experimental group). experimental group, detection rate isup grade group 1 cancers reduced half (detection ratio: 0.46, 95% ci: 0.33–0.64, p < 0.001); isup grade group ≥ 2 cancers lower significantly different (detection ratio: 0.81, 95% ci: 0.60 1.1). reference group, ten 68 men isup grade group ≥ 2 cancer diagnosed systematic biopsy only. ten patients intermediate risk. thus, screening setting, ‘mri pathway’ may reduce risk over-diagnosis half, cost delaying detection intermediate-risk tumours small percentage patients. however, good results obtained single academic centre double reading mri, may limit generalisability less experienced centres (see sections 5.5.4). ip1-prostagram study (psa > 3 ng/ml; mri pirads [prostate imaging – reporting data system] > 2), tested mri initial screening test, showed highest detection cspca mri compared psa threshold followed transrectal ultrasound-guided prostate (trus) biopsy population screening setting, similar rates biopsy insignificant cancer . study proposed pathway combines psa >=1 ng/ml mri score >=4, maintaining detection grade group ≥2 cancers recommending fewer men biopsies, preferred strategy evaluate future studies first screening round .